A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs MAGE A-10 TCR-transduced lymphocytes (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Adaptimmune
- 08 Jan 2018 Results published in an Adaptimmune Media Release
- 02 Jan 2018 Planned End Date changed from 4 Apr 2019 to 1 Apr 2019.
- 02 Jan 2018 Planned primary completion date changed from 3 Apr 2019 to 1 Apr 2019.